Columbia Laboratories’ Board of Directors set a ratio of 1-for-8 for its reverse stock split

NewsGuard 100/100 Score

Columbia Laboratories, Inc. ("Columbia" or the "Company") (NasdaqCM: CBRX) announced today that its Board of Directors (the "Board") has set a ratio of 1-for-8 for its previously approved reverse stock split of its common stock, and an anticipated effective date for the reverse stock split of the later of (i) the filing with the Secretary of the State of Delaware of a certificate of amendment with respect to the reverse stock split or (ii) August 9, 2013. The reverse stock split was approved by the Company's stockholders at its annual meeting of stockholders on May 1, 2013, where the Company's stockholders granted to the Board the authority to amend the Company's certificate of incorporation to effectuate a reverse stock split of its Common Stock at a ratio of up to and including 1-for-10, as determined by the Board.

No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu of such fractional share. American Stock Transfer & Trust Company, LLC will act as exchange agent for the Reverse Stock Split.

Source: Columbia Laboratories, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.